Benzinga · Aug 12, 2026
Alterity Therapeutics Secures Key US Patent for Lead Asset
Alterity Therapeutics secured a USPTO patent for ATH434, extending market protection for its neurodegenerative drug candidate to 2045.
AT
NASDAQ · ATHE
Alterity Therapeutics Limited
Healthcare · Biotechnology
$4.57
Down-$0.10 (-2.14%)
Updated Aug 25, 2026, 11:21 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 31.19M
- P/E ratio
- -4.93
- Dividend yield
- 0.00%
- 52-week range
- $3.09 – $5.89
- Volume
- 10.6K
- Avg. volume
- 14.18K
Price performance
ATHE price history
1M range · 21 trading sessions · Daily adjusted prices
ATHE closed at $4.57 after 21 trading sessions, down 2.04% for the selected period.
- Last close
- $4.57
- Period change
- -2.04%
- Period low
- $4.37
- Period high
- $4.91
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $4.65 | $4.75 | $4.48 | $4.57 | 10.6K |
| Aug 21, 2026 | $4.60 | $4.72 | $4.51 | $4.67 | 10.59K |
| Aug 20, 2026 | $4.60 | $4.7031 | $4.35 | $4.45 | 21.03K |
| Aug 19, 2026 | $4.56 | $4.90 | $4.31 | $4.80 | 43.61K |
| Aug 18, 2026 | $4.58 | $4.59 | $4.50 | $4.5628 | 9.44K |
| Aug 17, 2026 | $4.79 | $4.81 | $4.55 | $4.57 | 30.83K |
| Aug 14, 2026 | $4.71 | $4.84 | $4.65 | $4.79 | 7.46K |
| Aug 13, 2026 | $4.84 | $4.84 | $4.60 | $4.70 | 19.52K |
| Aug 12, 2026 | $5.01 | $5.04 | $4.78 | $4.91 | 26.04K |
| Aug 11, 2026 | $4.70 | $4.7999 | $4.58 | $4.70 | 6.05K |
| Aug 10, 2026 | $4.37 | $4.72 | $4.37 | $4.545 | 6.52K |
| Aug 7, 2026 | $4.545 | $4.545 | $4.39 | $4.45 | 1.39K |
| Aug 6, 2026 | $4.70 | $4.70 | $4.53 | $4.56 | 2.92K |
| Aug 5, 2026 | $4.37 | $4.50 | $4.37 | $4.37 | 1.97K |
| Aug 4, 2026 | $4.32 | $4.425 | $4.32 | $4.3941 | 2.3K |
| Aug 3, 2026 | $4.42 | $4.74 | $4.31 | $4.4568 | 3.67K |
| Jul 31, 2026 | $4.34 | $4.78 | $4.34 | $4.415 | 3.79K |
| Jul 30, 2026 | $4.20 | $4.6599 | $4.20 | $4.495 | 9.53K |
| Jul 29, 2026 | $4.50 | $4.7413 | $4.44 | $4.44 | 2.15K |
| Jul 28, 2026 | $4.68 | $4.68 | $4.565 | $4.565 | 2.21K |
| Jul 27, 2026 | $4.60 | $4.75 | $4.54 | $4.665 | 3.9K |
Latest ATHE news
The latest Smart Investors Daily articles mentioning ATHE.
Stock researchCompany · Overview
ATHE research
Overview
Company profile and research snapshot.
Company profile
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | CANACCORD GENUITY | Buy | — |
| Jan 5, 2018 | B. Riley FBR | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12
Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $12.
Benzinga · Jul 7, 2026
Alterity Therapeutics Receives Official Meeting Minutes From Fda End-of Phase-2 Meeting For ATH434 In Multiple System Atrophy; Pivotal Phase 3 Trial Activities On Track To Initiate By End Of 2026
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced
Benzinga · Jun 30, 2026
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16
Jones Trading analyst Debanjana Chatterjee initiates coverage on Alterity Therapeutics (NASDAQ:ATHE) with a Buy rating and announces Price Target of $16.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
